Advanced central nervous system (CNS) lymphoma is an exclusion criterion for most
chimeric antigen receptor (CAR) T-cell studies due to the associated levels of neurotoxicity …

Chimeric antigen receptor (CAR) T-cell immunotherapy is a new strategy for the treatment of
refractory B-cell malignancies; therefore, the rapid and accurate quantification of CAR …

The treatment of refractory Burkitt's lymphoma (BL) is still a challenge. Although CAR-T cell
therapy has achieved good responses in diffuse large B cell lymphoma, there is no case …

Background CAR-T cell therapy is effective in the treatment of certain hematological
malignancies, and the expansion and functional persistence of CAR-T cells in vivo are …

Gastrointestinal (GI) tract is the most common site of extranodal involvement in non-Hodgkin
lymphoma. Life-threatening complications of GI may occur because of tumor or …

Liquid biopsy is a promising technique for tumor genetic profiling and evaluating disease
progression. Recent advances in circulating tumor DNA (ctDNA) research highlight its utility …

The rapid spread of coronavirus disease 2019 (COVID‐19) represented the most serious
issue to public health globally. Hematological patients as immunocompromised hosts are …

Internal tandem duplication (ITD) mutations of FMS-like tyrosine kinase-3 (FLT3) are the
most frequent genetic alterations in acute myeloid leukemia (AML) and predict a poor …

Background Hemophagocytic lymphohistiocytosis (HLH) associated with B-cell lymphoma is
a highly aggressive disease with unclear clinical features and has no standard treatment …

Background The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a
dismal prognosis. Dual targeting BTK and BCL2 with ibrutinib and venetoclax has improved …